8-AZABICYCLO(3.2.1)OCTANE-2-CARBOXYLIC ACID, 3-(4-FLUOROPHENYL)-8-((2E)-3-IODO-2-PROPEN-1-YL)-, METHYL ESTER, (1R,2S,3S,5S)-
Parkinsonian Syndromes
Alseres Pharmaceuticals, IncSmall moleculePhase 3Dormant
B
60/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 45/ 100
- Competitive Position
- 95/ 100
Competitive context
0 Active assets in the Parkinsonian Syndromes cohort.
| Asset / Sponsor | Phase | Rating |
|---|---|---|
.BETA.-CIT Institute for Neurodegenerative Disorders | Phase 2 | BBB |
IOFLUPANE GE Healthcare | Phase 3 | BB |
Ctc-501 Institute for Neurodegenerative Disorders | Phase 2 | B |
LEVODOPA Institute for Neurodegenerative Disorders | Phase 2 | B |
BLOOD, WHOLE University Hospital, Bordeaux | D |
View all 10 →
Same molecule, other indications
8-AZABICYCLO(3.2.1)OCTANE-2-CARBOXYLIC ACID, 3-(4-FLUOROPHENYL)-8-((2E)-3-IODO-2-PROPEN-1-YL)-, METHYL ESTER, (1R,2S,3S,5S)- is also rated in:
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →